INDIVIOR INC.
RICHMOND, VA

Indivior Inc., founded in Richmond, Virginia, operates with a profound commitment to addressing the global challenge of addiction. Tracing its origins back to the establishment of the Buprenorphine Business Group by Reckitt Benckiser in 1994, Indivior has been engaged for over two decades in innovating treatments for opioid use disorders and beyond. The company has since expanded into a multi-faceted enterprise with operations across more than 40 countries. Central to Indivior's mission is its patient-focused business model, anchored on three strategic pillars: investing in product innovation; broadening access infrastructure for patients; and fostering engagement with stakeholders such as governments, healthcare providers, and advocacy groups. Noteworthy developments include collaborations like the agreement with AntiOp, Inc. in February 2014 to co-develop a naloxone nasal spray for opioid overdose reversal and the licensing deal with XenoPort, Inc., aimed at advancing treatments for alcohol use disorders. Indivior's evolution from its inception as part of Reckitt Benckiser Pharmaceuticals Inc. is marked by significant milestones including its incorporation in September 2014 and the December 23rd demerger leading to a listing on the London Stock Exchange. The company's leadership, comprising dedicated individuals such as Richard Simkin (Director), Ryan Preblick (Treasurer), and Mark W Crossley (Director), is committed to addressing unmet treatment needs while navigating the complex landscape of addiction treatment. With operations headquartered at 10710 Midlothian Turnpike, Richmond, Virginia, Indivior continues to prioritize patient safety, encouraging open communication regarding product concerns or adverse events. To learn more about Indivior’s innovative approach to transforming global health outcomes in addiction medicine and its comprehensive range of products, visit [indivior.com](http://www.indivior.com).